Taiwanese (TAIEX) Life Sciences Industry Analysis
UpdatedFeb 01, 2023
DataAggregated Company Financials
Companies7
- 7D9.8%
- 3M14.4%
- 1Y13.0%
- YTD2.8%
Over the last 7 days, the Life Sciences industry has remained flat. As for the the longer term, the industry is up 5.5% over the past 12 months. As for the next few years, earnings are expected to grow by 119% per annum.
Industry Valuation and Performance
Has the Taiwanese Life Sciences Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Wed, 01 Feb 2023 | NT$49.8b | NT$2.7b | NT$85.3m | 19.3x | 583.6x | 18.6x |
| Fri, 30 Dec 2022 | NT$50.0b | NT$2.7b | NT$85.3m | 18.8x | 586.4x | 18.7x |
| Sun, 27 Nov 2022 | NT$51.3b | NT$2.7b | NT$139.5m | 18.5x | 367.9x | 19.2x |
| Tue, 25 Oct 2022 | NT$43.7b | NT$3.0b | NT$482.8m | 23.1x | 90.5x | 14.6x |
| Thu, 22 Sep 2022 | NT$45.6b | NT$3.0b | NT$482.8m | 25.6x | 94.4x | 15.2x |
| Sat, 20 Aug 2022 | NT$41.7b | NT$3.0b | NT$498.3m | 25.2x | 83.6x | 13.7x |
| Mon, 18 Jul 2022 | NT$38.5b | NT$3.1b | NT$325.1m | 37.3x | 118.3x | 12.5x |
| Wed, 15 Jun 2022 | NT$40.7b | NT$3.1b | NT$325.1m | 36.6x | 125.2x | 13.3x |
| Fri, 13 May 2022 | NT$28.8b | NT$2.9b | NT$80.8m | 27.4x | 356.8x | 9.8x |
| Sun, 10 Apr 2022 | NT$34.8b | NT$3.2b | NT$164.4m | 27.6x | 211.4x | 10.9x |
| Tue, 08 Mar 2022 | NT$34.2b | NT$3.0b | -NT$120,147,000.00 | 34.9x | -284.4x | 11.2x |
| Thu, 03 Feb 2022 | NT$35.8b | NT$3.0b | -NT$120,147,000.00 | 34.3x | -298.1x | 11.8x |
| Sat, 01 Jan 2022 | NT$39.0b | NT$3.0b | -NT$120,147,000.00 | 37.6x | -324.4x | 12.8x |
| Mon, 29 Nov 2021 | NT$38.5b | NT$3.0b | -NT$120,147,000.00 | 37.9x | -320.4x | 12.6x |
| Wed, 27 Oct 2021 | NT$29.4b | NT$2.8b | -NT$511,386,000.00 | 23.4x | -57.4x | 10.4x |
| Fri, 24 Sep 2021 | NT$36.2b | NT$2.3b | -NT$631,150,000.00 | 31.8x | -57.3x | 15.6x |
| Sun, 22 Aug 2021 | NT$36.7b | NT$2.3b | -NT$631,150,000.00 | 32x | -58.2x | 15.8x |
| Fri, 09 Jul 2021 | NT$41.2b | NT$2.3b | -NT$631,150,000.00 | 33x | -65.3x | 17.7x |
| Thu, 01 Apr 2021 | NT$27.9b | NT$2.2b | -NT$810,177,000.00 | 29x | -34.4x | 12.9x |
| Sun, 03 Jan 2021 | NT$14.9b | NT$2.2b | -NT$912,568,000.00 | 25.2x | -16.3x | 6.7x |
| Wed, 07 Oct 2020 | NT$19.2b | NT$2.1b | -NT$914,668,000.00 | 21.9x | -21x | 9x |
| Tue, 30 Jun 2020 | NT$19.5b | NT$1.8b | -NT$1,161,248,000.00 | 20.7x | -16.8x | 10.7x |
| Fri, 03 Apr 2020 | NT$8.0b | NT$1.8b | -NT$951,923,500.00 | 18.3x | -8.4x | 4.4x |
Price to Earnings Ratio
-9.5x
Current Industry PE
- Investors are optimistic on the Taiwanese Life Sciences industry, and appear confident in long term growth rates.
- The industry is trading at a PE ratio of 531x which is higher than its 3-year average PE of 4.9x.
- The 3-year average PS ratio of 11.6x is lower than the industry's current PS ratio of 16.9x.
Past Earnings Growth
- Total earnings for the Life Sciences industry have gone up over the last three years, and the industry is now profitable. Revenues have grown 17% per year.
- This means that more sales are being generated by the industry overall, and subsequently profits are increasing too.
Industry Trends
Which industries have driven the changes within the Taiwanese Healthcare industry?
| TW Market | 2.33% | |
| Healthcare | 3.71% | |
| Life Sciences | 9.82% | |
| Clinical Research and Equipment | 9.82% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 6589 EirGenix | NT$117.00 | 7.3% +NT$2.4b | 16.4% | PS24x | |
| 6891 Locus Cell | NT$46.35 | 30.7% +NT$2.2b | n/a | PB4.8x | |
| 4133 Abnova (Taiwan) | NT$38.60 | 1.6% +NT$36.3m | -18.1% | PE37.9x | |
| 6661 Welgene BiotechLtd | NT$22.80 | 2.2% +NT$11.7m | 4.1% | PE20.7x |